Niedźwiedzi
Pfizer's stock declines 1.2% amid cautious analyst sentiment and CFO departure
Ten briefing nie jest jeszcze dostępny w tym języku — wyświetlana jest wersja angielska.
Pfizer's stock experienced a 1.2% decline, closing at $24.75 on July 20, 2026. This downturn is attributed to cautious analyst sentiment, with several firms recently lowering price targets, and the announcement of CFO Dave Denton's departure, effective August 15. Despite reaffirming its 2026 revenue guidance of $59.5 billion to $62.5 billion, the stock's consensus rating remains 'Hold' with an average target price of $28.50.
Kluczowe punkty
- Analysts have recently reduced price targets for Pfizer, contributing to a cautious outlook.
- The announcement of CFO Dave Denton's departure has raised concerns among investors.
- Pfizer has reaffirmed its 2026 revenue guidance, indicating stability in its financial outlook.
Źródła
Wygenerowane przez AI na podstawie publicznych źródeł wiadomości. To nie jest porada finansowa.
